Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2010

Wu Jenn-Yu, Yu Chong-Jen, Shih Jin-Yuan, Yang Chih-Hsin, Yang Pan-Chyr

Abstract excerpt

PURPOSE: Gefitinib is a valid second-line therapy for previously treated non-small cell lung cancer (NSCLC) patients. The influences of various chemotherapy regimens and EGFR mutations on effectiveness of second-line gefitinib are not clear, and laboratory studies revealed that previous chemotherapy changed the effectiveness of treatment with gefitinib. In order to clarify the factors changing the effectiveness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 19473721
DOI: 10.1016/j.lungcan.2009.04.018

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.PMID 19473721Read ↗

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.Semantic proximity Read ↗

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.Semantic proximity Read ↗

Gefitinib for advanced non-small cell lung cancer.Semantic proximity Read ↗

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.